AGENDA
Uniform Formulary Beneficiary Advisory Panel
8 January 2015 @ 0900 AM
Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004

➢ Administrative Meeting (BAP members only @ 7:45 AM-9:00 AM)
➢ Sign-In
➢ Welcome and Opening Remarks
➢ Public Citizen Comments
➢ Therapeutic Class Reviews

Members of the DHA Pharmacy Operations Division Formulary Management Branch will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The P&T Committee made recommendations for the following drug classes during the November 2014 meeting:

➢ Designated Newly Approved Drugs
  o Insulin Drugs: Miscellaneous Insulin Devices—V-Go
  o Pulmonary Drugs: Chronic Obstructive Pulmonary Disease—umeclidinium/vilanterol inhaler (Anoro Ellipta)
  o Glaucoma Drugs—brinzolamide 1%/brimonidine 0.2% ophthalmic suspension (Simbrinza)
  o Ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)—Prolensa

➢ Drug Class Reviews:
  o Multiple Sclerosis Drugs (MS)
  o Self-Monitoring Blood Glucose System (SMBGS) Test Strips

➢ Utilization Management Issues
  o Prior Authorization Criteria
    ▪ Hepatitis C Virus Drugs: Direct Acting Antivirals—ledipasvir/sofosbuvir (Harvoni) and simeprevir (Olysio)
    ▪ Targeted Immunomodulatory Biologics (TIBs)—adalimumab (Humira), apremilast (Otezla), and etanercept (Enbrel)
- Prostate Cancer Drugs—enzalutamide (Xtandi)
- Non-Insulin Diabetes Mellitus Drugs: Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs)—exenatide once weekly pen formulation (Bydureon pen)
- Compounded Prescriptions

Panel Discussions

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.